JIN MEDICAL INTERNATIONAL LTD. (ZJYL) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of JIN MEDICAL INTERNATIONAL LTD. $2.90, price $2.05, upside +41.5%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
42‑month range $1.81 – $276.11 · fair‑value band $2.03 – $3.57 · the $2.05 price screens below the $2.90 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares in your weekly email
Every Wednesday you see whether JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury.
Show more
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury. The company offers wheelchairs and wheelchair components, such as wheels and brakes; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers. It operates in the Mainland China, Japan, the United States, Hong Kong, Singapore, Korea, Australia, and internationally. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. operates as a subsidiary of Jolly Harmony Enterprises Limited.
Stock analysis
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) currently trades at $2.05, while our model-based Fair Value estimate is $2.90, implying the stock looks roughly 29.3% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $2.97 per share, and 9 of the 12 models we run sit above the $2.05 price.
Bear case: the Earnings-Based group reads lowest at $1.47, and 3 of the 12 models stay below the price. Evidence for this calculation is medium.
Scenario range: $2.03 (bear) to $3.57 (bull), the price of $2.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported revenue of $20.7M in FY2025 versus $20.8M in FY2021, a compound −0.1%/yr. Reported net income was $1.2M in FY2025, compounding −18.0%/yr from FY2021.
Key figures
Market cap $19.3M · P/E ratio 12.3 · P/S ratio 0.71 · EPS (TTM) $0.2000 · Net margin 5.8% · Return on equity 4.8% · Return on assets (EBIT) 8.0% · Operating margin 9.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 83% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 41%, ZJYL screens cheaper than that median.
Fair Value models
Bear $2.03Fair Value $2.90Bull $3.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.1973 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−3.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 3%
Compare JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside+42% · Top 25%
Profitability
Return on equity (TTM)5% · Below median
Return on assets1% · Bottom 25%
Net margin (TTM)6% · Below median
Operating margin (TTM)10% · Below median
Growth and dividend
Revenue growth−17% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/ZJYL
Frequently asked questions
Is JIN MEDICAL INTERNATIONAL LTD. (ZJYL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $2.90 versus a price of $2.05, about +41% upside (undervalued).
What is the fair value of ZJYL?
Our model-based fair value for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is $2.90 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.05.
What is the quality score of ZJYL?
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
Our model-based price target is the fair value of $2.90 (as of Sep 23, 2026) from 12 valuation models. Cautious scenario $2.03, optimistic scenario $3.57. It is a calculation from audited fundamentals, not an analyst target.
What is the JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares stock forecast for 2026?
Our models put fair value at $2.90, about +41% upside versus a price of $2.05 (undervalued). Cautious scenario $2.03, optimistic scenario $3.57. The calculation is refreshed regularly with new filings.
What is the revenue of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported trailing-twelve-month revenue of about $20.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares it is $2.90 per share (as of Sep 23, 2026), against a price of $2.05. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ZJYL trades below its calculated fair value: price $2.05, fair value $2.90, a gap of about +41% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZJYL?
No. The price is what the market pays today ($2.05); the fair value is what the company's own numbers justify ($2.90). For JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares the two are $0.8500 per share apart. That gap is exactly why we show both numbers side by side.
How much is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares worth?
The market values JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares at about $19.3M (market capitalisation, as of Sep 23, 2026). Per share that is $2.05; our models calculate a fair value of $2.90 per share.
What do the bullish and bearish scenarios say about ZJYL?
Our models span a range for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares: cautious scenario $2.03, base $2.90, optimistic $3.57 per share (as of Sep 23, 2026, price $2.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZJYL?
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares trades at a price-to-earnings ratio of 12.3 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.90 is built from several models across several years. Other multiples: P/B 0.7, P/S 0.9, EV/EBITDA 13.9.
How solid is the balance sheet of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
Balance-sheet figures for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (as of Sep 23, 2026): return on equity 4.8%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is ZJYL from its 52-week high?
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares trades at $2.05, about 83% below its 52-week high of $11.76 and 13% above the low of $1.81 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $2.90 is for.
Which stocks are comparable to JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares stock attractive at the current price?
The data as of Sep 23, 2026: price $2.05, calculated fair value $2.90 (+41%), Quality Score 29/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZJYL calculated?
We run JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
The closing price on Sep 23, 2026 was $2.05. Our model-based fair value is $2.90, about +41% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares right now?
The large discount to fair value meets weak quality (29/100). That raises the risk this is a value trap rather than a bargain. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
How large is the market capitalisation of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
The market capitalisation of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is $19.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
The price-to-sales ratio of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is 0.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
Earnings per share at JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares are $0.2000 (price ÷ EPS = P/E 12.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
The net margin of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is 5.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
The return on equity (ROE) of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is 4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
On an EBIT basis the return on assets of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
The operating margin of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is 9.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
Revenue at JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is growing −16.5% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JIN MEDICAL INTERNATIONAL LTD. (ZJYL)?
Earnings per share at JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares are growing −32.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does JIN MEDICAL INTERNATIONAL LTD. (ZJYL) generate?
The free cash flow of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is −$3.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does JIN MEDICAL INTERNATIONAL LTD. (ZJYL) carry?
The net debt of JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares is $11.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares in the live analysis
One click puts JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026